Biodexa Pharmaceuticals annual return on equity
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Return on Equity (ROE) Growth & History (BDRX)
Biodexa Pharmaceuticals's return on equity was −64.72% for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −64.72% | +23.41 pp |
| 2024 | 2024-12-31 | −88.14% | +92.45 pp |
| 2023 | 2023-12-31 | −180.59% | −68.11 pp |
| 2022 | 2022-12-31 | −112.47% | −48.87 pp |
| 2021 | 2021-12-31 | −63.60% | +105.29 pp |
| 2020 | 2020-12-31 | −168.89% | −113.60 pp |
| 2019 | 2019-12-31 | −55.29% | +2.97 pp |
| 2018 | 2018-12-31 | −58.26% | −18.30 pp |
| 2017 | 2017-12-31 | −39.96% | +3.58 pp |
| 2016 | 2016-12-31 | −43.54% | — |
Biodexa Pharmaceuticals return on equity trends
Over the last five fiscal years, Biodexa Pharmaceuticals's return on equity increased from −168.89% to −64.72%, a change of +104.17 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...